Heron Therapeutics

SUSTOL

Manufacturer:

Heron Therapeutics

Sustol HCPCS:

J1627

HCPCS Code Descriptor:

Injection, granisetron, extended-release, 0.1 mg

Category:

J Code

Sustol NDCs:

47426-0101-06

Primary Type:

Oncology-Anti-Emetic

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Sustol:

SUSTOL is an Oncology-Anti-Emetic drug manufactured by Heron Therapeutics and administered via the Subcutaneous route of administration. The J Code: J1627 is aligned to the drug SUSTOL.

Sustol is a medication indicated for the prevention of nausea and vomiting caused by cancer treatment. Sustol may be used to prevent nausea in patients undergoing chemotherapy, or who have recently had surgery. Sustol is thought to work by blocking the natural substance serotonin in the body, as serotonin may trigger nausea and vomiting. Sustol may be used in combination with other anti-nausea medications.

ACCESS PRICING AND MORE BY REGISTERING

J1627 Added Date:

January 1, 2018

J1627 Effective Date:

January 1, 2018

J1627 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Sustol billing and coding information.
Sustol patient assistance information can be found through Heron Connect at the URL: http://www.heronconnect.com/
SUSTOL prescribing information can be found at the link below:
Information regarding SUSTOL’s side effects can be found at MedlinePlus